Nurix Therapeutics 2026 annual meeting votes: directors elected, auditor ratified, say-on-pay approved

Nurix Therapeutics, Inc.

Elected all three Class III director nominees: Arthur T. Sands (63.6M for, 16.3M withheld), Roger Dansey (79.6M for, 0.3M withheld), Paul M. Silva (59.3M for, 20.6M withheld).
Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026 with 83.6M for, 0.2M against, 0.02M abstentions.
Approved non-binding advisory vote on named executive officer compensation: 72.5M for, 6.9M against, 0.6M abstentions, 3.8M broker non-votes.
Approximately 81% of voting power (83.7M shares) present, establishing a quorum.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.